HRTX — Heron Therapeutics Balance Sheet
0.000.00%
- $160.82m
- $255.88m
- $154.90m
Annual balance sheet for Heron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 158 | 84.9 | 80.4 | 59.3 | 46.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 35.5 | 52 | 60.1 | 78.9 | 89.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 254 | 205 | 189 | 209 | 238 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 33.6 | 29.8 | 25.6 | 17.6 | 12.4 |
| Other Long Term Assets | |||||
| Total Assets | 306 | 251 | 223 | 233 | 256 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 71.1 | 82.4 | 79.7 | 91.5 | 96.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 228 | 237 | 256 | 267 | 242 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 77.6 | 13.6 | -34 | -33.7 | 14.3 |
| Total Liabilities & Shareholders' Equity | 306 | 251 | 223 | 233 | 256 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |